fr   en

Browse by date
Or search by keyword
Date: 2010-08-10
Biotech partner: NsGene (Denmark) Biogen Idec (USA)
Type of agreement: * licensing
* commercialization/ distribution
* development
Compound: Neublastin (disease-modifying therapeutic protein)
Disease area: neuropathic pain
Development phase: Phase I
Nature of the agreement: NsGene A/S has executed a new and expanded license and commercialisation agreement with Biogen Idec on Neublastin, a therapeutic protein currently in Phase I development for the
treatment of neuropathic pain under the agreement with Biogen Idec.
Financial terms of the agreement: The expanded agreement grants Biogen Idec extended rights to Neublastin and secures NsGene an upfront payment of $ 6 million, and an annual maintenance fee of $1.5 million. The maintenance fee is to be paid in those years in which NsGene does not receive a development milestone and until acceptance of the first regulatory filing for approval of a Neublastin product.
In addition, NsGene will receive increased royalties on future sales of Neublastin products. Development milestones will be paid in accordance with the agreement from year 2000.

Go back to previous page